"In May 2003, Easton led a $55.3 million financing for Acorda Therapeutics,
one of the top three private biotechnology financings to date in 2003. Easton's ability to lead
such a significant round, particularly in a challenging financial environment, is a testament to
its capabilities and excellence. Acorda's management and Board were thoroughly impressed by the
acumen and performance of the people at Easton. They comprise a rare mix of expertise in finance,
life sciences, business development and value creation, together with meticulous attention to detail
and passionate commitment. We are especially pleased that John Friedman has joined our Board of
Directors, where we expect his insights to contribute substantially to Acorda's future successes."
Ron Cohen
Founder, President, and CEO, Acorda Therapeutics
Sanarus Medical
Sanarus Medical is focused on developing and marketing minimally
invasive devices for the diagnosis and treatment of breast tumors.
Sanarus is in the early commercialization of its Visica(r) Treatment
System, for cryoablation of breast fibroadenomas. The Visica Treatment
System offers women a minimally invasive, office based procedure to
definitively treat benign breast tumors versus the traditional treatment
of open surgical removal. Easton led an investment in Sanarus in
January 2007. Other investors in the Company include Mosaix Ventures,
U.S. Venture Partners, Forward Ventures, Alta Partners, Federated
Kaufmann Fund, Pequot Ventures, Industry Ventures and CHANNEL Medical
Partners.